Shots:
- LabGenius has entered into a multi-year research collaboration, option & licensing agreement with LG Chem to identify next-generation multispecific antibodies for difficult-to-treat cancers, leveraging LabGenius’ AI/ML-driven antibody discovery platform, EVA
- As per the licensing deal, LabGenius will lead preclinical research, incl. in vitro efficacy studies, after which LG Chem will conduct further preclinical development, incl. in vivo studies, & retain an option to in-license the program
- LabGenius will receive an undisclosed upfront payment, potential early milestones, and, if LG Chem exercises its option, potential triple-digit million clinical, regulatory, & commercial milestones, plus royalties on net sales. LG Chem will fund all R&D activities under the collaboration
Ref: Businesswire | Image: LabGenius & LG Chem | Press Release
Related News: Frontier Medicines Grants Ex-China Rights of FMC-220 to LG Chem
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
